Michael Crackower

Michael Crackower

Company: Ventus Therapeutics

Job title: Chief Scientific Officer


Identification of Structurally Distinct, Potent & Selective Brain Penetrant and Peripherally Restricted NLRP3 Inhibitors 2:30 pm

Using our proprietary platform, we have identified numerous structurally distinct series of NLRP3 inhibitors that selectively bind to NLRP3 with high affinity The compounds comprise highly brain penetrant as well as peripherally restricted compounds Our lead compounds have a best-in-class potency and pharmacology profile and are highly active in vivoRead more

day: Day 2 - Track B - Afternoon

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.